An aqueous pharmaceutical formulation comprising the thrombin inhibitor melagatran and use of the formulation in the manufacture for use by nasal administration in treating thromboembolism

摘要

An aqueous pharmaceutical formulation comprising the thrombin inhibitor HOOC-CH₂-(R)-Cgl-Aze-Pab (melagatran), or a pharmaceutically-acceptable derivative thereof, a process for the preparation of such a pharmaceutical formulation, the use of such a formulation in the treatment of thromboembolism as well as a method of treating a patient in need of antithrombotic treatment and thromboembolism by using said formulation via nasal administration.